Eliquis® (also known by its generic name Apixaban) is a blood-thinning medication that is part of a class of drugs known as novel oral anticoagulants. Eliquis®, manufactured by Bristol-Myers Squibb and Pfizer Inc., first earned approved for sale in the U.S. market on Dec. 28, 2012. The Food and Drug Administration approved Eliquis® for the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, prevention of blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism) in patients undergoing hip or knee replacement surgery, and treatment of DVT and PE (including recurrent DVT or PE).
Eliquis® is marketed and sold as a supposedly safer and easier-to-use (e.g., more convenient) alternative to the well-established blood thinning medication Coumadin® (warfarin). The manufacturers of Eliquis® have spent millions of dollars aggressively promoting the drug by touting that users don’t have to (a) avoid certain foods that interact with warfarin and (b) do not have to undergo routine blood monitoring and dose adjustment. Although all blood thinning medications have the risk of causing bleeding, unlike warfarin, the effects of which can be reversed by the use of vitamin K, Eliquis® has no known reversal agent. This means there’s no reliable way to stop dangerous bleeding caused by Eliquis®.
The Institute for Safe Medication Practices ISMP, a nonprofit organization dedicated to safe medication use, stated in its QuarterWatch publication on Sept. 23, 2015, that “[a]s previously noted in this publication, bringing a new generation of oral anticoagulants to market based on ease of use rather than improved safety was a major wrong turn.”
The ISMP went on to comment that “the risks of bleeding are so high that individualizing the dose—as with warfarin—promises to improve the safety profile of this risky class of drugs.”
All federal lawsuits that allege bleeding injuries caused by Eliquis® have been assigned to Judge Denise Cote in the United States District Court for the Southern District of New York, who has appointed Burg Simpson shareholder Seth A. Katz as Co-Lead Counsel in this litigation.
By the end of 2014 – when Eliquis® had been on the market for only one year – users reported more than 1,000 Serious Adverse Events to the FDA, including more than 100 patients who died while using the drug. As part of the litigation, victims of Eliquis®-induced bleeding allege the manufacturers overstate the efficiency of Eliquis® in marketing the drug.
Bleeding events possibly caused by Eliquis® include:
- Gastrointestinal bleeding
- Bleeding in the brain
- Bleeding resulting in death
If you or a loved one suffered one of these injuries, you may have experienced some of the following signs or symptoms:
- Red, pink or brown urine; red or black stools (looks like tar)
- Coughing up or vomiting blood or vomit that looks like coffee grounds
- Headaches, or feeling dizzy or weak
- Unexpected bleeding or bleeding that lasts a long time, such as unusual bleeding from the gums, nosebleeds that happen often, or menstrual or vaginal bleeding that is heavier than normal.
No. We offer our clients a free, no-obligation case assessment by filling out the Free Case Evaluation form found on this page. We pay for the cost of obtaining your medical records, any expert reviews, and court filing fees. We only receive reimbursement and a fee for our work if the defendant manufacturer pays your claim. If you do not receive a recovery, then you owe Burg Simpson nothing.
As with any potential claim, there are time limits for filing a lawsuit. If you or a loved one has suffered the serious illnesses Eliquis® can cause, fill out the Free Case Evaluation form as soon as you can to discuss your case with a Colorado Mass Tort Attorney.